Of note, the FDA-approved non-phenolic antioxidant edaravone has been preclinically shown to increase Nrf2 levels in ALS patients (Ohta et al. 2019; Zhang et al. 2019b). This evidence concerns the gene NFE2L2 and amyotrophic lateral sclerosis.